Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
Rees has drawn attention to the importance and usefulness of the
new asthma guidelines, but he questioned the necessity of adding the
authors' view that senior medical staff should be consulted in a
situation where there is clear evidence of benefit (use of intravenous
magnesium for severe asthma).1
As a member of the group developing guidelines for the management of acute asthma for the British Thoracic Society-Scottish Intercollegiate Network, I would like to clarify the reason for including this advice in the guidelines. A weakness of the previous guidelines from the British Thoracic Society was the absence of clear advice concerning the involvement of senior staff in the care of patients at high risk. It was common for junior staff to manage severely ill patients and to administer treatments such as aminophylline, which could cause serious side effects without discussing the patient with senior staff.
Intravenous magnesium has